The announcement was welcome news for those with major depressive disorder, affecting an estimated 8.3% of the adult ...
An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration ...
The FDA approves Spravato, a nasal spray derived from Ketamine, to help some people treat depression. Dr. Bill Hartman from UW Health shares more.
Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven’t responded to oral antidepressants. On Tuesday, the Food and Drug Administration (FDA) ...
Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.
The U.S. Food and Drug Administration has approved a nasal spray that is known to help treat depression.
A nasal spray therapy for treatment-resistant major depressive disorder (MDD) has now been approved by the Food and Drug Administration (FDA) for use on its own, making it the first-ever approved ...
The US Food and Drug Administration has approved a new nasal spray for depression treatment. Known as Spravato and ...
In today's Health Alert, the FDA has approved the first stand-alone nasal spray to treat drug-resistant depression.
A large study of 30,000 adults diagnosed with ADHD in the U.K. found women with ADHD died roughly nine years younger than women without a diagnosis. Men had about a seven-year shorter lifespan.
This article explores insights from Richmond-area therapists on Ketamine-Assisted Psychotherapy (KAP) and EMDR therapy, focusing on their applications in treating trauma, CPTSD, and mental health ...